Palmitoylethanolamide for Nickel Allergy: Plausible, Untested, and Worth Considering

Area of Science:

• Dermatology and Immunology
• Gastroenterology
• Pharmacology

Background:

• Nickel allergy is a leading cause of allergic contact dermatitis globally, causing significant health and economic issues.
• Systemic nickel allergy syndrome involves gastrointestinal and skin symptoms triggered by dietary nickel, linked to gut barrier dysfunction and immune responses.
• Angiogenesis and lymph-angiogenesis, involving vascular endothelial growth factor, play a role in nickel-induced allergic contact dermatitis.

Purpose of the Study:

• To explore the therapeutic potential of palmitoylethanolamide (an endogenous ALIAmide) for nickel allergy.
• To highlight palmitoylethanolamide's anti-inflammatory, anti-angiogenic, and gut barrier-enhancing properties in the context of nickel hypersensitivity.
• To stimulate scientific discussion on using palmitoylethanolamide in gut-skin axis therapeutic strategies for nickel allergy.

Main Methods:

• Review of existing evidence on palmitoylethanolamide's mechanisms of action.
• Analysis of palmitoylethanolamide's role in mast cell degranulation and VEGF signaling (PPAR-α/Akt/mTOR).
• Evaluation of palmitoylethanolamide's impact on intestinal barrier integrity.

Main Results:

• Palmitoylethanolamide down-modulates mast cell degranulation, a key factor in allergic reactions.
• It suppresses VEGF expression, potentially reducing angiogenesis and lymph-angiogenesis in nickel allergy.
• It enhances intestinal barrier integrity, counteracting gut hyperpermeability associated with systemic nickel allergy.

Conclusions:

• Palmitoylethanolamide shows promise as a therapeutic agent for nickel allergic contact dermatitis and systemic nickel allergy.
• Its dual action on gut barrier enhancement and inflammation modulation makes it a potential "gatekeeper" molecule.
• Further experimental and clinical studies are encouraged to validate its use in integrated gut-skin therapeutic approaches.